Alaunos Therapeutics, INC Form 4 insider transactions

Holger Weis, CEO of Alaunos Therapeutics, Inc., received 4,363 shares of common stock on August 6, 2026.

Michael Allen Jerman, a Director of Alaunos Therapeutics, Inc., received 8,138 shares of common stock on July 23, 2026.

Robert W Postma, a Director of Alaunos Therapeutics, Inc., received 8,463 shares of common stock on July 23, 2026.

Alaunos Therapeutics CEO Holger Weis acquired 3,880 shares of common stock for $2.26 per share, issued in lieu of net salary.

Alaunos Therapeutics CEO Holger Weis acquired 7,761 shares of common stock for $2.26 per share, totaling $17,540.76, as part of a salary payment.

Alaunos Therapeutics CEO Holger Weis acquired 3,700 shares of common stock for $2.37 per share, issued in lieu of net salary.

Director Jaime Vieser acquired 6,515 shares of Alaunos Therapeutics common stock in lieu of board fees.

Director Robert Postma has acquired 6,274 shares of Alaunos Therapeutics common stock in lieu of cash board fees, signaling alignment with shareholder interests.

Alaunos Therapeutics Director Michael Allen Jerman acquired 5,406 shares of common stock at $2.89 per share, issued in lieu of board fees.

Alaunos Therapeutics Director Robert W. Postma acquired 5,622 shares of common stock at $2.89 per share in lieu of board fees.

Alaunos Therapeutics Director Jaime Vieser acquired 5,839 shares of common stock at $2.89 each, issued in lieu of board fees, as part of a pre-planned transaction.

Alaunos Therapeutics director Jaime Vieser acquired 5,340 shares of common stock at $3.16 per share in lieu of board fees, increasing beneficial ownership.

Alaunos Therapeutics Director Robert W. Postma acquired 5,142 shares of common stock at $3.16 per share, issued in lieu of board fees under a 10b5-1 plan.

Alaunos Therapeutics Director Michael Allen Jerman acquired 4,183 shares of common stock at $3.16 per share, issued in lieu of board fees.

Alaunos Therapeutics' Vice President of Finance, Ferdinand Groenewald, acquired 10,775 shares of common stock and 4,000 employee stock options.

Alaunos Therapeutics CEO Holger Weis was granted 13,676 employee stock options with an exercise price of $2.32, vesting on August 18, 2025.

Alaunos Therapeutics, Inc. Director Michael Allen Jerman was granted 13,200 employee stock options with an exercise price of $3.40 per share, vesting over time.

Robert W. Postma, a director of Alaunos Therapeutics, reported the acquisition of common stock and stock options, including vested restricted stock units, in a recent SEC filing.

Alaunos Therapeutics Director Jaime Vieser increased his beneficial ownership through a grant of 3,400 restricted stock units and 6,400 employee stock options.

Alaunos Therapeutics, Inc. has granted its Chief Executive Officer, Holger Weis, 130,000 employee stock options with an exercise price of $5.02.

Alaunos Therapeutics Director Jaime Vieser reported the acquisition of 250 shares of Series A-2 Convertible Preferred Stock, signaling insider confidence.

Robert W. Postma, a Director and 10% owner of Alaunos Therapeutics, Inc., has reported significant acquisitions of common stock and convertible preferred stock, increasing his beneficial ownership in the company.

Robert W. Postma, a director of Alaunos Therapeutics, recently acquired common stock and Series A-1 Convertible Preferred Stock, according to a Form 4 filing.

Holger Weis, a director of Alaunos Therapeutics, acquired 10,904 employee stock options on April 13, 2025, at an exercise price of $2.92.

Director Jaime Vieser acquired 17,465 shares of Alaunos Therapeutics common stock through a grant of restricted stock units.

Dale Curtis Hogue Jr., Chief Executive Officer of Alaunos Therapeutics, acquired 3,000 employee stock options on March 29, 2025.

Melinda Lackey, Legal & Administration Officer at Alaunos Therapeutics, acquires stock options as per SEC Form 4 filing.

Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, acquired stock options on March 29, 2025.

Director Jaime Vieser of Alaunos Therapeutics, Inc. (TCRT) sold a portion of their common stock holdings on December 31, 2024.

Ferdinand Groenewald, VP of Finance at Alaunos Therapeutics, acquired stock options on August 14, 2024.